Interestingly, there is growing evidence that AGL can be triggered by immune checkpoint inhibitors such as anti-programmed cell death protein 1 (PD-1) therapies, including pembrolizumab and nivolumab, used to treat metastatic melanoma and renal cell carcinoma [47–51]. This evidence concerns the gene PDCD1 and hereditary clear cell renal cell carcinoma.